Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Forthcoming | Report ID : ARC2596
Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium the thin layer of tissue that lines the joints and tendons. PVNS usually affects the knee, although it can affect other joints as well.
Market Dynamics
Increasing in-patients in hospitals related suffering from rare condition and demand for advanced treatment are factors expected to drive the growth of global pigmented villonodular synovitis treatment market. By 2040, nearly 80 million U.S. adults will have some form of arthritis diagnosed, according to the Centers for Disease Control and Prevention. In the US, 23% of all adults, or more than 54 million people, have arthritis. It is a leading cause of work disability, with annual costs for medical care and lost earnings of $303.5 billion. Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium the thin layer of tissue that lines the joints and tendons to thicken and overgrow. The mass or tumor that results from this overgrowth is not cancerous and does not spread (metastasize) to other areas of the body. Increasing R&D activities related to development of advanced treatment by the government and high spending on healthcare sector are factors expected to impact the growth of pigmented villonodular synovitis treatment market. Government is spending high on R&D activities; their collaborative approach with private players and high clinical trials for development of advance cure is gaining traction.
In 2019, Daiichi Sankyo Company, Limited announced that new data from a pooled analysis of the phase 3 ENLIVEN study and phase 1 extension study showed continued treatment with pexidartinib resulted in an increased tumor response rate in TGCT patients.
In 2017, Five Prime Therapeutics, Inc., a drug manufacturing company received approval from European Commission for orphan designation for cabiralizumab (FPA008) for the treatment of tenosynovial giant cell tumour, localised and diffuse type, also known as Pigmented Villonodular Synovitis (PVNS), a locally aggressive tumor of the synovium.
Favorable business policies by the government of developing countries and players inclination towards emerging economies due to low cost labor and easy availability of raw material are factors responsible for the market growth. Factors such as high cost of therapy and stringent government policy related to product approval are expected to hamper the growth of global pigmented villonodular synovitis treatment market. In addition, lack of developed infrastructure in developing countries is expected to challenge the growth of target market. However, increasing R&D activities by major player’s, focus on introduction of novel drugs, and increasing awareness among consumers related to new therapy are factors expected to create new opportunities for players operating in pigmented villonodular synovitis treatment market over the forecast period. In addition, high government spending on healthcare sector and increasing partnership activities are aspect responsible for revenue transaction of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global pigmented villonodular synovitis treatment market due to high patient pool suffering from arthritis. In addition, availability of advanced infrastructure for R&D activities and introduction of new drugs are factors expected to support the growth of target market. Major player’s inclination towards increasing the customer base and enhance the product portfolio is expected to augment the pigmented villonodular synovitis treatment market growth.
The market in Asia Pacific is expected to witness faster growth in the pigmented villonodular synovitis treatment market due to changing government regulations related to healthcare sector. In addition, favorable business policies and players approach towards emerging economies in order to track the untapped market are factor expected to support the regional market growth.
Competitive Landscape
The global pigmented villonodular synovitis treatment market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Pigmented Villonodular Synovitis Treatment Market Segment Analysis, 2019
The global pigmented villonodular synovitis treatment market is segmented into type of treatment and end user. The type of treatment segment is bifurcated into drug therapy, radiation therapy, and surgical operation. Among type of treatment the drug therapy segment is expected to account for major revenue share in the global pigmented villonodular synovitis treatment market. The end use segment is divided into hospitals, surgical clinics, and others. The players profiled in the report are Plexxikon, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company.
Market Segmentation
Market By Type of Treatment
Drug therapy
- Cabiralizumab
- Emactuzumab
- Mcs-110
- Nilotinib
- Others
Radiation therapy
Surgical operation
- Arthroscopy
- Open surgery
- Combined arthroscopic
- Open surgery
- Total joint replacement.
Market By End Use
Hospitals
Surgical clinics
Others
Market By Geography
North America
• U.S.
• Canada
Europe
• U.K.
• Germany
• France
• Spain
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
Frequently Asked Questions
Increasing in-patients in hospitals related suffering from rare condition and demand for advanced treatment are factors expected to drive the growth of global pigmented villonodular synovitis treatment market.
In type of treatment the drugs therapy segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Novartis AG, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company.
The North America is expected to account for major revenue share in the global market.
In end use the hospital segment is growing at faster pace.
Factors such as high cost of therapy and stringent government policy related to product approval are expected to hamper the growth of global pigmented villonodular synovitis treatment market.
